Currently, there are 971.00M common shares owned by the public and among those 939.80M shares have been available to trade.
The company’s stock has a 5-day price change of -9.55% and 0.36% over the past three months. CRM shares are trading 3.71% year to date (YTD), with the 12-month market performance up to 40.66% higher. It has a 12-month low price of $190.45 and touched a high of $318.71 over the same period. CRM has an average intraday trading volume of 5.55 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -9.59%, -8.54%, and 11.14% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Salesforce Inc (NYSE: CRM) shares accounts for 81.69% of the company’s 971.00M shares outstanding.
It has a market capitalization of $264.71B and a beta (3y monthly) value of 1.28. The stock’s trailing 12-month PE ratio is 64.90, while the earnings-per-share (ttm) stands at $4.21. The company has a PEG of 4.00 and a Quick Ratio of 1.02 with the debt-to-equity ratio at 0.23. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.31% over the week and 2.22% over the month.
Analysts forecast that Salesforce Inc (CRM) will achieve an EPS of $Arm Holdings plc for the current quarter, $122.32 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $Cel-Sci Corporation while analysts give the company a high EPS estimate of $Cornerstone Strategic Value Fd. Comparatively, EPS for the current quarter was $CorMedix Inc. a year ago. Earnings per share for the fiscal year are expected to increase by 19.16%, and 13.04% over the next financial year. EPS should shrink at an annualized rate of 16.22% over the next five years, compared to 24.06% over the past 5-year period.
Robert W. Baird coverage for the Salesforce Inc (CRM) stock in a research note released on January 11, 2024 offered a Outperform rating with a price target of $300. Morgan Stanley was of a view on December 21, 2023 that the stock is Overweight, while Wells Fargo gave the stock Equal Weight rating on December 20, 2023, issuing a price target of $280. Wolfe Research on their part issued Outperform rating on December 18, 2023.
